Detalles de la búsqueda
1.
Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
Circulation
; 139(14): 1661-1670, 2019 04 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30630341
2.
Pharmacodynamic Effects of Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease: Results of the SWAP-4 Study.
Circulation
; 137(23): 2450-2462, 2018 06 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29526833
3.
Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention.
J Transl Med
; 16(1): 92, 2018 04 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-29642909
4.
Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-Function Genotypes: Results of a Randomized Pharmacodynamic Study in a Feasibility Investigation of Rapid Genetic Testing.
JACC Basic Transl Sci
; 5(5): 419-428, 2020 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-32478205
5.
Effects of Edoxaban on the Cellular and Protein Phase of Coagulation in Patients with Coronary Artery Disease on Dual Antiplatelet Therapy with Aspirin and Clopidogrel: Results of the EDOX-APT Study.
Thromb Haemost
; 120(1): 83-93, 2020 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-31470444
6.
Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated With Potent Oral P2Y12 Receptor Inhibitors With and Without Aspirin: Results of the VORA-PRATIC Study.
J Am Heart Assoc
; 9(8): e015865, 2020 04 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-32306797
7.
Pharmacodynamic Effects of Vorapaxar in Patients With and Without Diabetes Mellitus: Results of the OPTIMUS-5 Study.
JACC Basic Transl Sci
; 4(7): 763-775, 2019 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-31998847
Resultados
1 -
7
de 7
1
Próxima >
>>